Take an in-depth look at San Diego's vibrant life sciences sector.

  • Innovative procedures, devices at area hospitals

    San Diego is home to several first-rate hospitals, many of which offer specialized procedures on the cutting edge of health care. Here we highlight a few procedures from the three largest hospital systems in the area, UC San Diego Health System, Scripps Health and Sharp HealthCare.

  • Large biotech leases fail to make an appearance

    Life science leasing activity in San Diego increased by 55 percent during the second quarter of 2013 over the first quarter, but large leases still prove elusive.

  • Local drug developers see record highs on Wall Street

    Treatments for psychosis, heart attacks, diabetes, cancers, hot flashes, bone disease and diarrhea helped propel some San Diego companies to record highs on Wall Street during the third quarter, although not all fared so well.

  • The Federal Circuit reverses the board on obviousness of combining known compounds

    The Federal Circuit, on an appeal from an inter partes reexamination proceeding, rejected the Patent Office Board of Patent Appeals and Interferences’ analysis of obviousness and objective indicia of nonobviousness in Leo Pharmaceutical Products, Ltd. v. Rea (Federal Circuit 2013).

  • A call to action: Restoring patent protections for innovations in biotechnology

    The dogma in U.S. patent law has been that subject matter is eligible for patent protection if it in any way involves the "hand of man" to transform a process or product from its form as it exists in nature. The biotechnology industry, and many of the well-known established biotechnology companies, flourished based on products produced from isolated DNA encoding bioactive molecules. A cornerstone of the success has been their ability to rely upon patent protection for their isolated DNA molecules and other biotechnological products and processes. Previous court decisions, including seminal Supreme Court decisions, upheld the finding that such products and processes are patent eligible.

Archived Reports

Inside Biotech - 2012

Get the details about a ballot initiative that could affect the biotech industry and discover why investing in biotech IPOs can reap rewards.